Actis, an investment firm specializing in growth markets, recently made a significant investment in Medis Group, a branded generic pharmaceuticals business based in North Africa. Medis was the first pharmaceutical company to launch sterile products in North Africa, and is responsible for building one of the first oncology laboratories on the continent. The company plans to extend its research and development pipeline into biosimilar medicines to treat diseases like infertility and multiple sclerosis.
Actis acquired their stake in Medis from Africinvest, a private equity firm specializing in African opportunities. The successful track record of Africinvest and other funds focused on African investments highlights the continent’s vast potential as an investment destination. According to Aziz Mebarek, Founding Partner at Africinvest, “Africinvest has achieved financial returns which have fully met the expectations of its shareholders.”
This is unsurprising, given that Africa offers an investment environment where high risk is balanced by the potential for very high rewards – and for investors with in-depth knowledge of the market and strong connections, the risks are significantly diminished.
Many investors from the Middle East are equipped with the knowledge required to invest in Africa, and rely on business facilitators to help them build their African network of contacts and source potential investment opportunities in the region.
The investment flows from the Middle East into Africa are part of a global trend. In 2015, there were 771 FDI (foreign direct investment) projects in Africa, up 7 percent from 722 projects in 2014. These projects were worth a total of 71.3 billion USD.
On October 4th, 2016, Naseba will be hosting the African Investments Meeting. At the meeting, pre-screened investors based in liquid Middle Eastern markets will be introduced to pre-qualified African investment opportunities.
Submit your business case:
Oops! We could not locate your form.
To learn more, contact:
Naseba investor introduction
+971 4 455 7954